Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!

Range Low Price High Price Comment
30 days $19.37 $25.53 Friday, 10th May 2024 NTLA stock ended at $24.46. This is 1.61% less than the trading day before Thursday, 9th May 2024. During the day the stock fluctuated 4.85% from a day low at $24.25 to a day high of $25.42.
90 days $19.37 $34.87
52 weeks $19.37 $47.48

Historical Intellia Therapeutics Inc prices

Date Open High Low Close Volume
Jul 26, 2023 $41.10 $42.30 $40.92 $41.98 497 406
Jul 25, 2023 $42.03 $42.77 $41.31 $41.37 451 857
Jul 24, 2023 $43.28 $43.56 $41.85 $41.92 539 239
Jul 21, 2023 $43.88 $44.08 $42.51 $43.37 784 200
Jul 20, 2023 $44.97 $45.39 $42.70 $43.28 727 695
Jul 19, 2023 $44.85 $46.00 $44.60 $45.62 882 180
Jul 18, 2023 $44.59 $44.82 $43.25 $44.18 901 147
Jul 17, 2023 $44.00 $45.67 $43.63 $44.13 688 232
Jul 14, 2023 $46.11 $46.21 $43.79 $43.96 723 709
Jul 13, 2023 $46.10 $46.50 $45.23 $45.78 821 955
Jul 12, 2023 $44.73 $45.98 $44.46 $45.77 1 102 702
Jul 11, 2023 $42.93 $43.98 $42.46 $43.49 737 574
Jul 10, 2023 $39.15 $43.19 $39.10 $42.90 1 125 459
Jul 07, 2023 $39.31 $40.02 $38.95 $39.35 682 369
Jul 06, 2023 $39.74 $39.74 $38.69 $39.12 811 994
Jul 05, 2023 $40.50 $40.71 $39.76 $40.45 679 264
Jul 03, 2023 $40.78 $41.41 $40.49 $40.71 484 675
Jun 30, 2023 $41.58 $41.90 $40.65 $40.78 792 010
Jun 29, 2023 $41.94 $42.37 $40.87 $40.90 1 157 740
Jun 28, 2023 $40.81 $42.15 $40.16 $42.15 789 692
Jun 27, 2023 $42.09 $42.09 $40.69 $40.80 688 733
Jun 26, 2023 $40.98 $42.24 $40.21 $41.88 745 025
Jun 23, 2023 $41.09 $41.88 $40.43 $40.98 1 599 699
Jun 22, 2023 $41.63 $42.41 $41.00 $41.98 771 404
Jun 21, 2023 $43.00 $43.45 $40.13 $41.85 1 304 047
Click to get the best stock tips daily for free!

About Intellia Therapeutics Inc

Intellia Therapeutics Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline... NTLA Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT